Format

Send to

Choose Destination
Onco Targets Ther. 2018 Dec 24;12:217-224. doi: 10.2147/OTT.S185710. eCollection 2019.

CUX2 functions as an oncogene in papillary thyroid cancer.

Author information

1
Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 32500, China, zhangxiaohua1126@163.com.

Abstract

Background:

In recent years, the incidence of thyroid cancer (TC), the most common endocrine malignancy, has been increasing. Emerging evidence indicates that the CUT/CUX/CDP family of proteins can play an important role in tumor development and progression by regulating many cancer-related functions. However, the molecular functions of CUX2 in TC remain unknown.

Methods:

In this study, we used a series of loss-of-function experiments and Western blot analysis to investigate the function of CUX2 in TC and the mechanisms involved.

Results:

Our data revealed that CUX2 expression levels were upregulated in papillary thyroid cancer (PTC). Functionally, CUX2 silencing significantly inhibited PTC cell line (KTC-1 and BCPAP) proliferation, colony formation, migration, invasion, and apoptosis. Furthermore, CUX2 induced epithelial-mesenchymal transition (EMT) and influenced the phosphorylation of AKT and mTOR in the PI3K-AKT-mTOR pathways.

Conclusion:

In summary, CUX2 may function as a tumor promoter in TC.

KEYWORDS:

CUX2; oncogene; papillary thyroid carcinoma

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center